Intrinsiqq
Strata Skin Sciences Inc. logo

Strata Skin Sciences Inc. Quality Score

SSKN

⊜ Compare
Quality0

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.0x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-0.0x

Negative FCF, no valuation support

Revenue Growth
0/100
-5.3%

Below 2%, essentially flat

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
34.0%

Heavy dilution above 5%

Margin Trend
0/100
-2.5pp

Contracted >2pp, margin pressure

Capital Structure
0/100
$8M

Positive debt with no FCF to service it

2022
$5.00M
$8.00M
2023
$7.00M
$16.0M
2024
$7.00M
$16.0M
2025
$8.00M
$16.0M
CashDebt
Return on Capital
0/100
-18.3%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Strata Skin Sciences (SSKN) quality: score, margins and returns

Strata Skin Sciences (SSKN) scores 0/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100, on -15.3% operating margins and -18.3% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Strata Skin Sciences (SSKN) a high-quality business?+

Strata Skin Sciences scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -15.3% operating margin and a -18.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Strata Skin Sciences's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from SSKN's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Strata Skin Sciences scores well and where it falls behind.

What is Strata Skin Sciences's return on invested capital (ROIC)?+

Strata Skin Sciences earns about -18.3% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to SSKN's margins and growth on this scorecard to judge durability.

How profitable is Strata Skin Sciences?+

Strata Skin Sciences runs an operating margin of about -15.3% and a net margin of about -20.4%. Revenue has grown at roughly 5.9% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-K filed 16 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with SSKN

CompareIntrinsic value
PREMPremier Air Charter Holdings Inc.
$0.02-20.00%15
OBIOOrchestra BioMed Holdings, Inc.
$6.00+7.91%40
RVPRetractable Technologies Inc.
$0.57+1.79%20
DYNTQDynatronics Corp
$0.00+0.00%29
UTMDUtah Medical Products Inc.
$72.42+3.43%40
IDXGInterpace Biosciences Inc.
$5.72+5.09%82
CTSOCytosorbents Corporation
$4.56+0.44%15
SNOASonoma Pharmaceuticals Inc.
$1.11-2.63%40

Spot a number that looks wrong? Check it in SSKN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SSKN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.